| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.26 | 6e-10 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.34 | 1e-09 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.25 | 2e-09 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.32 | 1e-08 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.21 | 8e-08 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | 0.22 | 2e-07 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.36 | 3e-07 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.21 | 3e-07 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.28 | 5e-07 |
| mRNA | selumetinib:PLX-4032 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.2 | 1e-06 |